Literature DB >> 2282335

Signal detection indices in schizophrenics on a visual, auditory, and bimodal Continuous Performance Test.

L Mussgay1, R Hertwig.   

Abstract

Signal detection indices (perceptual sensitivity) were calculated to compare performance of 24 male schizophrenic inpatients and 24 controls (12 alcoholics and 12 normals) on 4 different CPT-tests. A standard version (St) employed 1 target (P = 0.166) and 5 nontargets. In condition V stimuli were presented visually, in condition A acoustically and in condition VA bimodally (1 target (P = 0.333) and 1 nontarget). Compared to controls schizophrenics exhibited lower levels of perceptual sensitivity in all 4 conditions. They were especially impaired when stimuli were presented either acoustically or when they had to monitor 2 modalities simultaneously. Perceptual sensitivity of schizophrenics was significantly lower in conditions V, A, and VA than in condition St. For controls only condition VA led to lower values. Because St was always presented first, the possible explanation that vigilance decrement over time is responsible for the lowered perceptual sensitivity had to be ruled out. It could be shown that schizophrenics did not differ in sensitivity between conditions being later in task sequence. Controls, however, showed a slight decrement over time. Thus our finding should to a large extent be attributed to different task requirements. Response criterion beta yielded inconsistent results.

Entities:  

Mesh:

Year:  1990        PMID: 2282335     DOI: 10.1016/0920-9964(90)90014-x

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

Review 1.  Real-world cognitive--and metacognitive--dysfunction in schizophrenia: a new approach for measuring (and remediating) more "right stuff".

Authors:  Danny Koren; Larry J Seidman; Morris Goldsmith; Phillip D Harvey
Journal:  Schizophr Bull       Date:  2006-01-05       Impact factor: 9.306

2.  Attention and clinical symptoms in schizophrenia.

Authors:  B Cornblatt; M Obuchowski; D B Schnur; J D O'Brien
Journal:  Psychiatr Q       Date:  1997

Review 3.  Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?

Authors:  M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

4.  MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.

Authors:  Adam C Mar; Simon R O Nilsson; Begoña Gamallo-Lana; Ming Lei; Theda Dourado; Johan Alsiö; Lisa M Saksida; Timothy J Bussey; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2017-07-26       Impact factor: 4.530

5.  No Correlation Between Perception of Meaning and Positive Schizotypy in a Female College Sample.

Authors:  Ubuka Tagami; Shu Imaizumi
Journal:  Front Psychol       Date:  2020-06-12

6.  Applicability of the Test of Variables of Attention - T.O.V.A in Brazilian adults.

Authors:  Cláudia M Memória; Henrique C S Muela; Natália C Moraes; Valéria A Costa-Hong; Michel F Machado; Ricardo Nitrini; Luiz A Bortolotto; Monica S Yassuda
Journal:  Dement Neuropsychol       Date:  2018 Oct-Dec

7.  Developing a dynamic model of anomalous experiences and function in young people with or without psychosis: a cross-sectional and longitudinal study protocol.

Authors:  Abigail C Wright; David Fowler; Kathryn E Greenwood
Journal:  BMJ Open       Date:  2018-11-03       Impact factor: 2.692

8.  The Impact of Poor Nonverbal Social Perception on Functional Capacity in Schizophrenia.

Authors:  Victoria Chapellier; Anastasia Pavlidou; Lydia Maderthaner; Sofie von Känel; Sebastian Walther
Journal:  Front Psychol       Date:  2022-02-23

9.  Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice.

Authors:  J W Young; M A Geyer; A J Rissling; R F Sharp; L T Eyler; G L Asgaard; G A Light
Journal:  Transl Psychiatry       Date:  2013-11-12       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.